A Pan-Cancer Analysis of the Oncogenic Role of Twinfilin Actin Binding Protein 1 in Human Tumors

Huo, Gengwei; Wang, Yali; Chen, Jinliang; Song, Ying; Zhang, Cuicui; Guo, Hua; Zuo, Ran; Zhu, Fuyi; Cui, Jinfang; Chen, Weidong; Chen, Wen-Ming; Chen, Peng

doi:10.3389/fonc.2021.692136

Cited by 17 publications

(12 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We obtained the OS and DFS (disease-free survival) from GEPIA2 platform, and RFS (recurrence-free survival) from the Kaplan–Meier Plotter platform ( www.kmplot.com ) to explore the prognostic value of XRCC4 in human cancers across all TCGA tumors. [ 20 , 21 ]. The median XRCC4 expression was used as the threshold to classify the high-expression and low-expression subgroups [ 18 ].…”

Section: Methodsmentioning

confidence: 99%

Systematic analysis identifies XRCC4 as a potential immunological and prognostic biomarker associated with pan-cancer

Sun

et al. 2023

BMC Bioinformatics

View full text Add to dashboard Cite

Background XRCC4 is a NHEJ factor identified recently that plays a vital role in repairing DNA double-stranded breaks. Studies have reported the associations between abnormal expression of XRCC4 and tumor susceptibility and radiosensitivity, but the potential biological mechanisms by which XRCC4 exerts effects on tumorigenesis are not fully understood. This study aimed to systematically investigate the role of XRCC4 across cancer types. Methods The TIMER, GTEX and Xiantao Academic database were used to interpret the expression of XRCC4. Genomic alterations and protein expression in human organic and tumor tissues were applied in cBioPortal and the Human Protein Atlas databases. Correlations between XRCC4 expression and immune and molecular subtypes were analyzed by using the TISIDB database. Protein–protein interactions, GO and KEGG enrichment were also applied for XRCC4-related genes. The TIMER and the Tumor Immune Single Cell Hub (TISCH) online databases were used to explore the relationship between XRCC4 and tumor immune microenvironment. Drug sensitivity information was acquired from the CellMiner database to analyze the effect of XRCC4 on sensitivity analysis. Results The XRCC4 expression was significantly upregulated in 15 tumor types and downregulated in two tumor types compared with the normal tissues, most of which were validated by the results of Xiantao academic platform. XRCC4 was expressed at intermediate level in malignant cells. The XRCC4 expression was related to the molecular and immune subtypes of human cancers, and the survival outcome of 11 types of cancers, including KIRC, STAD and LIHC. The main type of frequent genetic alteration is amplification. Strong correlations were also found between XRCC4 and immune checkpoint genes in 33 human cancers. Furthermore, the abnormal expression of XRCC4 was related to immune cell infiltration and drug sensitivity. Enrichment analysis showed that XRCC4 was significantly correlated with DNA damage response. Conclusions This comprehensive pan-cancer analysis suggested that XRCC4 may play a vital role in the prognosis and immunotherapy response in cancer patients, and it is a promising therapy target in the future.

show abstract

Section: Methodsmentioning

confidence: 99%

Systematic analysis identifies XRCC4 as a potential immunological and prognostic biomarker associated with pan-cancer

Sun

et al. 2023

BMC Bioinformatics

View full text Add to dashboard Cite

show abstract

“…The R package of “tidyr” and “ggplot2” were used to visualise the enrichment pathways. R software (R-4.0.2, 64-bit) was used in this study ( https://www.r-project.org/ ), and statistical significance was set at p < 0.05 ( Cui et al, 2020 ; Huo et al, 2021 ).…”

Section: Methodsmentioning

confidence: 99%

New Insights Into PTBP3 in Human Cancers: Immune Cell Infiltration, TMB, MSI, PDCD1 and m6A Markers

Fang

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Polypyrimidine tract binding protein 3 (PTBP3) plays a critical role in post-transcriptional regulation. The role of PTBP3 in various human tumours was explored and analysed in this study based on the Cancer Genome Atlas and Gene Expression Omnibus datasets. PTBP3 was highly expressed in most tumours, such as breast invasive carcinoma, colon adenocarcinoma and hepatocellular carcinoma. PTBP3 overexpression generally predicts poor overall survival and disease-free survival in patients with adrenocortical carcinoma, lung squamous cell carcinoma, and pancreatic adenocarcinoma. However, low PTBP3 expression predicts poor prognosis in kidney renal clear cell carcinoma. We also explored PTBP3 genetic alterations in different tumour tissues. The result found that the frequency of PTBP3 alteration (>4%) was the highest in uterine tumours with “mutation” as the primary type. Furthermore, we found a significant correlation between PTBP3 expression and tumour mutational burden and microsatellite instability in various human tumours, and found that PTBP3 expression was positively correlated with TMB in ACC, STAD, PAAD, LUAD, and SARC. Two enhanced phosphorylation levels of S30 and S426 in colon cancer, ovarian cancer, and uterine corpus endometrial carcinoma were found. Further analysis indicated that PTBP3 expression was positively correlated with the cancer-associated fibroblasts for most tumour types. This study also found a relationship between immune checkpoints and N6-methyladenosine-related markers and PTBP3 expression. Moreover, the “mRNA surveillance pathway” and “RNA degradation” were involved in the functional mechanisms of PTBP3. These results provide new insights for molecular studies, and integrative analysis provided a framework for determining the predictive, prognostic, and therapeutic relevance of PTBP3 in cancer patients.

show abstract

“…After logging in to TIMER2 ( http://timer.cistrome.org/ ), we went to the “immune” module, clicking on “gene”, entered “DYRK2”, and selected “cancer associated fibroblast” in “Immune Infiltrates”. The TIMER, CIBERSORT, CIBERSORT-ABS, QUANTISEQ, XCELL, MCPCOUNTER and EPIC algorithms were used to evaluate immune infiltration 32 .…”

Section: Methodsmentioning

confidence: 99%

A pan-cancer analysis of the oncogenic role of dual-specificity tyrosine (Y)-phosphorylation- regulated kinase 2 (DYRK2) in human tumors

Qiu

Shen

Zhao

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Although there have been studies correlating DYRK2 with a number of human cancers, there has been no pan-cancer analysis. Therefore, through the TCGA database, we conducted a related study on the expression of DYRK2 in cancers.The expression of DYRK2 is obviously increased in some cancers, while the opposite is true in others, and there is a clear association between its expression and the prognosis of cancer patients.The mutation of DYRK2 is also significantly correlated with patients’ prognosis in certain human tumors. In addition, phosphorylation and methylation levels of DYRK2 are different between tumor tissues and adjacent normal tissues in various tumors. In the tumour microenvironment, the expression of DYRK2 correlates with cancer-associated fibroblast infiltration, such as BLCA or HNSC. In order to fully understand the role of DYRK2 in different tumors, we conducted a pan-cancer analysis.

show abstract

A Pan-Cancer Analysis of the Oncogenic Role of Twinfilin Actin Binding Protein 1 in Human Tumors

Cited by 17 publications

References 27 publications

Systematic analysis identifies XRCC4 as a potential immunological and prognostic biomarker associated with pan-cancer

Systematic analysis identifies XRCC4 as a potential immunological and prognostic biomarker associated with pan-cancer

New Insights Into PTBP3 in Human Cancers: Immune Cell Infiltration, TMB, MSI, PDCD1 and m6A Markers

A pan-cancer analysis of the oncogenic role of dual-specificity tyrosine (Y)-phosphorylation- regulated kinase 2 (DYRK2) in human tumors

Contact Info

Product

Resources

About